[Nature Metabolism] Researchers showed that ECM1 is an early regulator of kidney remodelling. Global Ecm1 knockout mice develop spontaneous fibrosis and early death, whereas ECM1 levels markedly increase in biofluids during chronic kidney disease.

[ACS Nano] Investigators proposed an ECM-biomimetic microenvironment-regulating coating, where a polyethylene glycol linker with antifouling effects is used to graft tailored recombinant humanized collagen type I possessing high cell-adhesive activity via an efficient click reaction.

[Advanced Healthcare Materials] Scientists developed a cascade reaction-enhanced sonodynamic therapeutic system that yields highly cytotoxic peroxynitrite (ONOO⁻). The resulting ONOO⁻ activates matrix metalloproteinases to degrade the ECM, thereby enhancing nanoparticle penetration and establishing a self-reinforcing antitumor cycle.

[Lab on a Chip] The authors created a microfluidic chip that recreates an inflammation event and directly isolates neutrophils from a small volume of whole blood using a 3D extracellular matrix.

[International Journal of Cancer] Scientists investigated whether the actin-related protein (Arp) 2/3 complex, a key actin nucleator, is essential for pancreatic ductal adenocarcinoma cells to overcome extracellular matrix stiffness and facilitate migration.

[ACS Biomaterials Science & Engineering] Researchers combined the bioactivity of decellularized ECM with the stability of norbornene hyaluronic acid granular hydrogels to create a system that promotes cell adhesion and allows for ECM release.

[Molecular Biology Reports] The authors combine ECM diagnostics, therapeutic targeting strategies, regenerative approaches, and computational models from a single precision medicine viewpoint.

[Trevi Therapeutics, Inc.] Trevi Therapeutics, Inc. announced the results of its End-of-Phase II meeting with the US FDA. The company plans to conduct two pivotal Phase III clinical trials and has obtained agreement on the remaining Phase I clinical studies that they expect to conduct to support the New Drug Application submission.

[Sumitomo Pharma Co., Ltd.] Sumitomo Pharma Co., Ltd. and and RACTHERA Co., Ltd., announced that Sumitomo Pharma has obtained conditional and time‑limited approval in Japan for the manufacturing and marketing authorization of the allogeneic iPS cell‑derived dopaminergic neural progenitor cell product AMCHEPRY^® for the indication of the improvement of motor symptoms in patients with Parkinson’s disease who have an inadequate response to existing pharmacological therapies.

[Signal Transduction and Targeted Therapy] Investigators presented a personalized treatment model using a patient-derived Networking Organoid Culture System composed of intestinal, liver, and kidney organoids differentiated from iPSCs of an NF1-mutant breast cancer patient.

[Science Advances] Scientists developed a method for differentiating male ESCs into functional embryonic testicular somatic cells, building upon the approach used for fetal ovarian somatic cell–like cells.

[Experimental & Molecular Medicine] Researchers investigated the role of DNA methyltransferase 3-like (Dnmt3L) in modulation of the DNA methylation and differentiation potential of mouse ESCs.